Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telescope InnovationsTELIF -1.94%30 Debt-to-Equity is 0.80 as of May. 2026, which is at its 10-year median of 0.80. GuruFocus rates TELIF with a GF Score™ of 30/100 and a GF Value™ of $0.39 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 967 Biotechnology companies, Telescope Innovations ranks worse than 84.69% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Telescope Innovations's Debt-to-Equity or its related term are showing as below:
TELIF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.35 Med: 0.8 Max: 12.61
Current: 0.8
During the past 7 years, the highest Debt-to-Equity Ratio of Telescope Innovations was 12.61. The lowest was -0.35. And the median was 0.80.
TELIF's Debt-to-Equity is ranked worse than 84.69% of 967
companies
in the Biotechnology industry
Industry Median: 0.16
vs TELIF: 0.80
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Telescope Innovations Debt-to-Equity Related Terms
Telescope Innovations Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Telescope Innovations's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELIF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Telescope Innovations's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telescope Innovations Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telescope Innovations's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Telescope Innovations's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telescope Innovations (TELIF) has a Debt-to-Equity of 0.80 as of May. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Telescope Innovations and its competitors. This is near median its historical median of 0.80. According to the industry distribution chart, Telescope Innovations ranks #819 out of 967 companies in the Biotechnology industry, placing it in the top 84.7%.
Is Telescope Innovations' Debt-to-Equity too high?
Telescope Innovations' current Debt-to-Equity of 0.80 is near median its 10-year median of 0.80. The Biotechnology industry median Debt-to-Equity is 0.16. Telescope Innovations' value of 0.80 is 400% above this industry median. Based on the distribution chart, Telescope Innovations ranks #819 out of 967 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Telescope Innovations has a GF Score™ of 30/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Telescope Innovations' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telescope Innovations ranks #819 out of 967 companies for Debt-to-Equity. This places Telescope Innovations in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Telescope Innovations' value of 0.80 is 400% above this benchmark. While the company's 10-year median is 0.80 vs. the industry median of 0.16, Telescope Innovations has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telescope Innovations's current Debt-to-Equity of 0.80 is 400% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Telescope Innovations and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telescope Innovations's current Debt-to-Equity is 0.80, which is near median its own 10-year median of 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telescope Innovations stock overvalued right now?
Based on GuruFocus' analysis, Telescope Innovations (TELIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.39, compared to a current price of $0.31 — trading 21% below its estimated fair value. The current Debt-to-Equity is 0.80, which is near median its 10-year median of 0.80 and 400% above the Biotechnology industry median of 0.16. Telescope Innovations' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Telescope Innovations (TELIF), the current Debt-to-Equity is 0.80 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telescope Innovations (TELIF) Overvalued in 2026?
Based on GuruFocus' analysis, Telescope Innovations stock appears to be undervalued.
The current stock price of $0.31 is trading 21% below its estimated GF Value™ of $0.39.
GuruFocus considers Telescope Innovations to be Modestly Undervalued.
Key valuation signals for TELIF:
Debt-to-Equity: 0.80 (near median its 10-year median of 0.80)
GF Value™: $0.39 vs. price of $0.31 (21% below fair value)
Industry Position: 400% above the Biotechnology median (#819 of 967)
No single metric tells the full story. See the TELIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telescope Innovations Corp is a technology company focused on development as a Contract Research Organization (CRO) to develop intellectual property, provide contract research, and build automation products, and operates as a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. Its flagship product is the DirectInject-LC system. The Company operates in a single operating segment and generates revenue from three streams: contract research services, grant income, and the sale of automation products, with the majority of revenue derived from automation product sales from customer contracts. It operates in Canada, the United States, Europe, and Asia, with the majority of revenue coming from the United States.
30GF Score
Get the complete analysis for TELIF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELIF has been successfully added to your 
